ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIBThe addition of CTC-DNA analysis to clinical trials could identify patients ...

0.04% of the stock is currently owned by insiders. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, ...

JPMorgan Chase & Co. reissued their overweight rating on shares of AstraZeneca (LON:AZN – Free Report) in a report issued on ...

Pomerantz LLP is investigating claims on behalf of investors of  AstraZeneca PLC ("AstraZeneca" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646 ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

We recently compiled a list of the 10 Best UK Stocks to Invest in Now. In this article, we are going to take a look at where ...

At the close in Stockholm, the OMX Stockholm 30 lost 1.01%. The best performers of the session on the OMX Stockholm 30 were ...

Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating on November 6. Andrew ...

Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...

(Alliance News) - AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps.